A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

NCT04417894 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Atopic Hand and Foot Dermatitis

Interventions

DRUG: dupilumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]